Safety
Avodart (dutasteride) Soft Gelatin Capsules June 2008
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- June 2008
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format. |
| Sections Modified | Summary of Changes to Contraindications and Warnings |
|
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONS
PATIENT COUNSELING INFORMATION
|
CONTRAINDICATIONS Pregnancy - Dutasteride inhibits the activity of 5α-reductase, which prevents conversion of testosterone to dihydrotesterone, a hormone necessary for normal development of male genitalia. In animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. Therefore, Avodart may cause fetal harm when administered to a pregnant woman. If Avodart is used during pregnancy or if the patient becomes pregnant while taking Avodart, the patient should be apprised of the potential hazard to the fetus... WARNINGS AND PRECAUTIONS Evaluation for Other Urological Diseases ...Patients should be assessed to rule out prostate cancer and other urological diseases prior to treatment with Avodart and periodically thereafter... Effects on Prostate-Specific Antigen (PSA) and the Use of PSA in Prostate Cancer Detection Coadministration of tamsulosin with dutasteride resulted in similar changes to total PSA as dutasteride monotherapy. |







